Loading...
•
Dec 31, 2025
Nuwellis Q4 2025 Earnings Report
Nuwellis reported modest revenue growth and improved gross margin but continued to post a quarterly operating loss as it focused on operational restructuring and commercial execution.
Key Takeaways
Nuwellis generated modest revenue growth in Q4 2025 driven by higher console sales and improved pricing, which also lifted gross margin. However, the company continued to operate at a loss as operating expenses exceeded gross profit while maintaining a limited cash position.
Q4 revenue increased to $2424000, up 4% year-over-year.
Gross margin improved significantly to 68.2% from 58.4% in the prior year quarter.
Net loss attributable to common shareholders was $2421000 for the quarter.
Cash and cash equivalents at quarter end totaled $1085000.
Forward Guidance
Nuwellis expects to focus on commercial execution, integration of the Rendiatech acquisition, and continued development of pediatric technologies while strengthening its capital position.
Positive Outlook
- Acquisition of Rendiatech expected to expand the cardiorenal product portfolio.
- Improving utilization trends in key product lines.
- Strong gross margin expansion in the quarter.
- Capital position strengthened through private placement financing.
- Development progress on Vivian pediatric solution supported by NIH grant funding.
Challenges Ahead
- Company continues to report operating and net losses.
- Limited cash reserves relative to ongoing operating needs.
- Revenue scale remains small with modest growth.
- Reliance on external financing to support operations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...